NYSE •
Healthcare •
Biotechnology •
Quote as of 08/24/2026 10:05
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization2.44 mln
Float4.42 mln
Earnings Date08/07/2026
EPS
0.98
Decent
P / E
0.52
Anomalous
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
9
/ 100
Severely lagging
Debt / Equity
0.01
Debt-free
ROE
-220
Deeply negative
Business Description
Oragenics is a US-based pharmaceutical company focused on developing treatments for brain and infectious diseases, delivered through the nose rather than by injection or pill. Their primary drug candidate, ONP-002, is a lab-made compound designed to pass through the brain's protective barrier, where it works to reduce swelling and inflammation while improving blood flow in patients with mild traumatic brain injuries. Founded in 1996 and based in Lakewood Ranch, Florida, the company continues to advance its pipeline of therapies through ongoing research and development.